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Abstract: Metabolic syndrome (MetS) greatly increases the risk of cardiovascular diseases and type
2 diabetes mellitus. The aim of this study was to evaluate the efficacy of functional snacks containing
a combination of wakame (W) and carob pod (CP) flours in reducing markers associated with MetS.
The mechanisms of action underlying these effects were also evaluated. In vitro approaches were
carried out in mature 3T3-L1 adipocytes and RAW 264.7 macrophages treated with different doses of
extracts from W, CP, or a combination of both. Furthermore, an in vivo experiment was conducted
in rats with MetS treated with normal-caloric diets containing different snack formulations with
combinations of 1/50 (snack A) or 1/5 of wakame/carob (snack B). In vitro experiments results
indicated that both W and CP had delipidating effects, but only the latter induced anti-inflammatory
and anti-hypertensive effects. As far as the in vivo study is concerned, snack B was ineffective and
snack A showed an anti-hypertensive effect in rats with MetS. The present study shows for the
first time the in vitro efficacy of a W and CP combination as an anti-inflammatory, delipidating,
and anti-hypertensive tool, and its potential usefulness in treating MetS.
Keywords: metabolic syndrome; rats; functional snack; in vitro; wakame; carob
1. Introduction
Metabolic syndrome (MetS) is a cluster of risk factors associated to cardiovascular disease
and type 2 diabetes mellitus (T2DM), mainly suffered by Western populations [1]. According to
the clinical classification of the National Cholesterol Education Program Adult Treatment Panel
IIII [2], the five factors (among which at least three must be followed) for the definition of MetS
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are: hypertriglyceridemia, waist circumference increase, low HDL-cholesterol, high blood pressure,
and fasting hyperglycemia. Among the causes that exacerbate this syndrome are age, genetic
conditions, and an inadequate lifestyle, including a sedentary lifestyle and the consumption of
high-calorie foods, rich in carbohydrates, saturated fats, and salt [3].
Hypotheses about the etiology of MetS consider the chronic state of the inflammatory pattern as
the starting point, since this may degenerate to insulin resistance and/or cardiovascular diseases [4].
It has also been observed that adipose tissue plays a role in some pathophysiological mechanisms involved
in the development of dyslipidemia, insulin resistance, and T2DM. Thus, today it is recognized as a key
tissue of insulin resistance and that the MetS is related to it [5]. White adipose tissue (WAT) mass is
defined by the size and number of adipocytes. Consequently, metabolic processes occurring inside
adipocytes such as de novo lipogenesis, lipolysis, glucose uptake, triglyceride synthesis, fatty acid
oxidation, apoptosis, or adipogenesis are essential to determine fat mass [6].
Due to the side effects associated with currently available drugs, as well as their limited efficacy [7],
in recent decades, the potential of natural products in combating MetS has aroused great interest
in scientific research [8]. Natural products from plant and marine sources, including their isolated
extracts or bioactive components, have been demonstrated to be effective in the prevention and
treatment of MetS and its co-morbidities [9,10]. Brown algae (Phaeophyceae), rich in chlorophylls,
sterols, carotenoids, and polyunsaturated fatty acids, have shown positive effects on health, such as
anti-hyperglycemic activity, antioxidant properties, and anti-obesity capacity, in animal models [11].
These algae are regularly consumed in Asian countries, such as Korea or Japan. Among brown
algae, the Undaria pinnatifida (Wakame) is one of the most important. The major components of
U. pinnatifida include carbohydrates, such as monosaccharides, polysaccharides (including sacran,
mannan, and xylan), and dietary fiber; in lower proportion it contains lipids, proteins, vitamins,
amino acids, and its derivatives, such as methacrylic acid and tauric acid, minerals, as well as
some phytochemicals, including flavonoids, alkaloids, and sterols [12–14]. There are numerous
animal studies that support its potential use against obesity, dyslipidemia, inflammation, and insulin
resistance [15,16]. Results found by our group, also highlight the wakame (W), among other algae,
for its anti-inflammatory, anti-hypertensive, and fat-lowering effects [17].
As in the case of algae, pulses are also capturing researchers’ attention due to their healthy
properties [18]. This is especially true of the carob tree (Ceratonia siliqua L.). Many studies confirm that
the fruit of the carob tree may have benefits on human health and may be used both as a preventive
or therapeutic agent for certain chronic diseases, and is of great interest for the prevention and
management of diabetes or hyperlipidemia [19].
Carob fruit is mainly composed of sugars, including sucrose, glucose, and fructose (48–56%), fibers
such as cellulose, hemicellulose, and lignin (30–40% in carob’s pulp), gum (85% of carob seed is composed
of galactomannan), amino acids, and minerals (mainly potassium and calcium). Furthermore, it also
contains phenolic compound. The concentration of compounds in carob fruit ranges from 45–5376 mg
gallic acid equivalents 100 g−1 and depends on genetic and environmental factors [19]; the main
groups are phenolic acids, hydrolysable, and condensed tannins [20].
The potential use of carob pod (CP) and W in the prevention or treatment of human MetS can
be addressed through different strategies; in this regard a simple approach would be to include it
in the diet as a functional food. Basic research on bioactive ingredients has some limitations, dose
being one of the most important. Sometimes doses used for bioactive components, both in vitro and
with experimental animals, are very high in comparison with clinical trials or with levels achieved
according to bio-availability. In fact, the low concentration of W bioactive compounds included in the
diet could be the reason that explains the lack of body fat reduction in some studies [21] compared to
others where the effect was observed [15]. In this context, in recent years, one of the strategies most
used in the development of functional foods is the combination of functional ingredients [22]. In the
present research, the efficacy of new functional snacks based on the combination of W and CP flour for
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MetS treatment was evaluated. The mechanisms of action underlying these effects observed by the
combination of W and CP were also analyzed.
2. Results
2.1. In Vitro Fat-Lowering Effect Evaluation and Anti-Hypertensive Activity of W, CP, and Their
Combined Extracts
With the exception of CP at 50 µg/mL, all the tested extracts demonstrated significant delipidating
effect in 3T3-L1 mature adipocytes (Figure 1A). W extracts reduced triglycerides (TG) content by
21% and 25% at 1 µg/mL and 10 µg/mL doses, respectively. TG decrease reached 32% with CP
(100 µg/mL), and 27% with a W 10 µg/mL + CP 50 µg/mL combination. It should be highlighted
that the combination of CP (50 µg/mL) with W (1 µg/mL) extract produced the maximum reduction
observed (−36%).
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Figure 1. In vitro fat-lowering effect, adipose tissue gene expressions, and anti-hypertensive activity
of wakame (W), carob pod (CP), and its combination (W+CP). (A) Mature 3T3-L1 adipocytes were
treated with 95% ethanol (control) or W (1 or 10 µg/mL), CP (50 or 100 µg/mL), and W+CP (1 µg/mL
+ CP 50 µg/mL or 10 µg/mL + CP 50 µg/mL) extracts diluted in 95% ethanol for 24 h, and TG
content was a alyzed. Ethanol concentration in the medium never exceeded 0.1%. Values of three
independent experi ents carried out i sextuplicate are expressed as mean ± SEM of the reduction
percentage compared with the control group (Y-axis). Data not sharing a common letter are significantly
different (p < 0.01). (B) mRNA levels of genes related to de novo lipogenesis, glucose uptake, apoptosis,
and TG assembly were measured. Data are presented as fold change mean± SEM of three independent
experiments carried out in sextuplicate, t < 0.1, ** p < 0.01, n.d.: not detected. (C) Angiotensin-converting
enzyme (ACE) inhibitory activity was evaluated. Values of three independent experiments carried out
in triplicate are expressed as a percentage mean of activity change ± SEM. Data not sharing a common
letter are significantly different (p < 0.01).
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With regard to in vitro anti-hypertensive activity, angiotensin-converting enzyme (ACE) inhibitory
activity, no significant effect was observed for the W extracts tested. By contrast, the lowest dose of CP
extract and its combination with W (W 1 µg/mL + CP 50 µg/mL) revealed significant reductions in
ACE activity (Figure 1C).
2.2. Gene Expression, Post-Transcriptional Lipolysis, and de Novo Lipogenesis Evaluation in Mature
Adipocytes Treated with W and CP Combined Extracts
In Figure 1B the expression of genes related to de novo lipogenesis, glucose uptake, apoptosis, and
TG assembly is shown. Mature adipocytes treated with the combination W 1 µg/mL + CP 50 µg/mL
showed a significant reduction in the expression diacylglycerol o-acyltransferase 1 (dgat1), solute carrier
family 2 member 4 (scl2a4) and a significant increase in BCL2-associated X protein (bax), when compared
with the control cells. In addition, a tendency towards reduced values was found in the expression of
fatty acid synthase (fasn).
The ratio acetyl-CoA carboxylase (ACC) phosphorylated/total ACC, an index of ACC activity,
was not modified after treatment with W and CP combination (Figure 2A). Similarly, no change for
FAS protein levels (Figure 2A) or FAS activity (Figure 2B) was detected. Glycerol release to the medium
did not vary after W 1 µg/mL + CP 50 µg/mL treatment (Figure 2C).
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Figure 2. In vitro effect of wakame (W), carob pod (CP), and its co i ( +CP) on the activity of
enzymes involved in de ovo lipogenesis and glycerol rel . (A) Mature T3-L1 adipocyt s were
incubated with 95% ethanol (control) or W 1 µg/ L + P 50 µg/mL extracts diluted in 95% ethanol
for 24 h, and Western blotting was used to determine the cleaved FAS, phosphorylated ACC (serine 79),
and total ACC protein expression. (B) β-actin was used as a loading control, and the quantified
expression levels of three independent experiments carried out in duplicates (percentage mean ± SD)
by Image software were plotted in the bar graphs. FAS activity (C) and glycerol release (D) to the
medium were determined using spectrophotometry. Values of the three independent experiments
carried out in duplicate are expressed as mean ± SEM.
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2.3. In Vitro Anti-Inflammatory of W, CP, and Their Combined Extracts
In RAW 264.7 macrophages, W extracts only reduced the production of nitric oxide (NO) without
a dose-response effect. The extracts of CP, as well as both combinations, reduced the production of
NO and prostaglandin D2 (PGD2) (Figure 3A,B). Tested extracts seemed to be ineffective on tumor
necrosis factor α (TNFα) reduction (Figure 3C). Marked differences were observed between W extracts
and the others. While the NO reduction for both W extracts was around −10%, this reached −60%
for CP (50 µg/mL) and the combination of extracts (W 10 µg/mL + CP 50 µg/mL, W 1 µg/mL + CP
50 µg/mL). In this line, a direct comparison between W and CP at the same dose, 10 µg/mL, revealed
higher NO-lowering effect for CP (−15%) than for W (−51%).
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(W+CP). RAW 264.7 macrophages were treat d with serum free medium (control) or W (1 or 10 µg/mL),
CP (50 or 100 µg/mL), and W+CP (1 µg/mL + CP 50 µg/mL or 10 µg/mL + CP 50 µg/mL) extracts
diluted in serum-free medium for 24 h and then stimulated with LPS. NO (A), PGD2 (B), and TNFα
(C) release to the medium was analyzed. Values of one independent experiment carried out in
sextuplicate are expressed as mean ± SEM of the reduction percentage compared with the control
group (Y-axis). The letter “c” represents values that are not significantly lower than those of the control
group. Data not sharing a common letter are significantly different (p < 0.01). (D) mRNA levels of
genes related to inflammation were measured. Data of one independent experiment carried out with
six replicates are presented as a fold change mean ± SEM; t < 0.1, * p < 0.05.
2.4. Gene Expression of RAW 264.7 Cells Treated with W and CP Combination
Lipopolysaccharide-stimulated RAW 264.7 macrophages treated with W 1 µg/mL + CP 50 µg/mL
reduced the xpr ssion of tnfα and interleukin 6 (il6) mRNA levels. More ver, a t ndency towards
reduced values was observed for cyclooxygenase 2 (cox2) gene expression (Figure 3D).
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2.5. Composition of Functional Snacks
The composition of snacks was evaluated. As expected, total carbohydrates and fiber content
were the major components: 43.5 and 22.9 g per 100 g of snack, respectively, in the case of snack A,
and 43.7, and 22.0 g 100 g−1, respectively, in the case of snack B. Fat level was 16.0 g 100 g−1 for 1:50
(W:CP) formulation and 16.1 g 100 g−1 for 1:5 formulation, meanwhile protein, water and ashes were
the minor components (11.9, 4.2, and 1.4 g 100 g−1, respectively in the case of snack A, and 12.2, 4.3,
and 1.6 g 100 g−1, respectively, in the case of snack B).
2.6. Food/Energy/Liquid Intake, Total Body Weights, White Adipose Tissue Weights, Interscapular Brown
Adipose Tissue Weights, and Gastrocnemius Muscle Weights in Rats Treated with Functional Snacks
No significant differences were observed among groups in final body weight, WAT weights,
interscapular brown adipose tissue weight, or gastrocnemius muscle weight (Table 1). Rats treated
with control diets (wheat control group -WC- and wheat-oat control group -OC-), as well as with diets
including functional snack (the snack A low-dose group -SAL-, the snack A high-dose group -SAH-,
and the snack B high-dose group -SBH-), showed lower water intake than MetS rats. No differences in
food intake or energy intake were observed between the experimental diets used to treat MetS (WC,
OC, SAL, SAH, and SBH) (Table 1).
Table 1. Initial and final body weight, food and water intake, and white adipose tissue weights of MetS
rats with treated experimental diets for 4 weeks.
MetS
n = 10
WC
n = 10
OC
n = 10
SAL
n = 10
SAH
n = 10
SBH
n = 10
Food intake (g/day) 20.8 ± 0.5 b 25.2 ± 1.4 a,b 28.4 ± 1.3 a 28.7 ± 1.2 a 25.5 ± 1.0 a,b 28.9 ± 1.5 a
Energy intake (kJ/day) 391 ± 9 b 418 ± 24 a,b 471 ± 22 a 473 ± 20 a,b 409 ± 19 a,b 463 ± 24 a,b
Water intake (mL/day) 21.6 ± 0.9 b 30.3 ± 0.2 a 28.3 ± 1.1 a 27.0 ± 1.1 a 29.1 ± 0.7 a 30.4 ± 1.9 a
Initial body weight (g) 202 ± 2.5 202 ± 2.8 202 ± 2.5 203 ± 2.5 203 ± 2.6 204 ± 2.7
Final body weight (g) 411 ± 10.3 456 ± 13.8 449 ± 4.9 441 ± 10.5 441 ± 8.3 448 ± 11.8
White adipose tissue weights
Epididymal (g) 11.7 ± 1.6 11.2 ± 1.2 12.2 ± 1.0 11.3 ± 0.8 11.7 ± 1.2 10.6 ± 1.2
Perirenal (g) 15.5 ± 1.4 16.1 ± 1.8 14.9 ± 1.0 14.5 ± 1.2 16.3 ± 1.5 14.8 ± 0.9
Mesenteric (g) 4.1 ± 0.4 5.0 ± 0.6 4.8 ± 0.3 5.2 ± 0.6 4.9 ± 0.4 4.4 ± 0.3
Subcutaneous (g) 14.1 ± 1.3 14.8 ± 1.6 13.9 ± 1.0 13.8 ± 1.0 14.0 ± 0.8 12.7 ± 0.4
∑ Adipose tissue (g) 45.4 ± 4.6 47.1 ± 4.9 45.8 ± 3.1 44.7 ± 3.5 46.9 ± 11.1 42.7 ± 2.9
∑ Adipose tissue/body weight (%) 10.9 ± 0.8 10.3 ± 0.9 10.2 ± 0.6 10.1 ± 0.7 9.4 ± 1.3 9.6 ± 0.7
IBAT weight (g) 1.46 ± 0.04 1.56 ± 0.10 1.40 ± 0.14 1.52 ± 0.08 1.57 ± 0.06 1.56 ± 0.08
∑ Gastrocnemius muscle weight (g) 4.58 ± 0.14 4.75 ± 0.16 4.18 ± 0.22 4.56 ± 0.13 4.90 ± 0.20 4.51 ± 0.26
IBAT: interscapular brown adipose tissue; MetS: Metabolic syndrome group; WC: wheat control group; OC:
wheat-oat control group; SAL: the snack A low-dose group; SAH: snack A high-dose group; SBH: snack B high-dose
group. Values are means ± SEM. Values in the same row with different subscripts are significantly different at
p < 0.05.
2.7. Blood Pressure and Renal ACE Activity in Rats Treated with Functional Snacks
At the beginning of the experiment (week 0 of treatment), when MetS was developed, systolic
blood pressure (SBP) and diastolic blood pressure (DBP) values were 139 ± 2 and 83 ± 2 Hg mm,
respectively. After the treatment, only the SAH group showed a significant decrease of SBP (p < 0.01)
(Figure 4A). No change in DBP was observed among different groups of rats (data not shown).
Rats treated with high doses of functional snacks modified ACE activity in kidneys compared with
MetS groups; more specifically, whereas the snack A reduced this enzymatic activity (p < 0.05), snack B
increased it (p < 0.01) (Figure 4B).
2.8. Anti-Inflammatory Activity in Rats Treated with Functional Snacks
No differences in C-reactive protein (CRP) serum levels were found among groups of rats
(Figure 4C). Rats fed the functional snacks (SAL, SAH, and SBH) showed lower monocyte chemotactic
protein 1 (MCP1) serum levels than MetS rats (Figure 4C). The most remarkable decrease was observed
in the SAH group, reaching statistical significance when compared with the WC group. In the case of
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IL6 serum levels, SAH treatment produced the most prominent decrease compared to the MetS group
(a 57% reduction). By contrast, SBH diet did not induce a significant modification (Figure 4C).
2.9. Functional Snacks Effect on Glycemic Control in MetS Rats
Insulin levels were increased in all expirmental groups in comparison with MetS rats, reaching
statistical significance in the case of OC and SBH groups (Figure 4D). Glucose levels were not modified
among different groups (Figure 4D). The inclusion of the snacks in the diet (SAL, SAH, and SBH
groups) reduced non-esterified fatty acids (NEFA) at the end of the experimental period (Figure 4D).
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3. Discussion
The present study aimed at analyzing the potential efficacy of new snacks prepared combining
W and CP for MetS treatment. Due to the fact that obesity is one factor included in the MetS,
the anti-obesity effects of these snacks were assessed. It has been described that obesity is associated
with a low-grade inflammatory status. WAT is infiltrated by macrophages, which together with
adipocytes, perpetuate a cycle of macrophage recruitment and secretion of free fatty acids deleterious
cytokines/chemokines predisposing to develop MetS [23]. Thus, in the present study the potential
anti-inflammatory effect of the snacks was also studied.
In order to address the objective proposed, the study followed two different approaches. First,
in vitro approach was carried out in 3T3-L1 using mature adipocytes and RAW 264.7 macrophages,
where the individual and combined effects of W and CP were evaluated. Second, an in vivo study
was performed in MetS rats fed a normal-caloric diet including two types of snacks based on the
combination of W and CP. W was chosen from the results of a previous screening study carried
out with seven seaweed species, where it was observed that W had the most effective bioactive
profile [17]. The dosage used for W and CP was selected on the basis of a previous work, as the
lowest dose with a significant effect (submitted data). Furthermore, the results from a sensory-panel
study, in which breads, including seaweeds or carob by-products were tested, was taken into account;
these experiments demonstrated that the presence of seaweeds reduced sensory properties more than
CP [24]. According to cell viability, doses as high as 50 µg/mL of W and CP were considered as
safe [17].
In cultured mature adipocytes, W showed a delipidating effect, either at the highest dose or at the
lowest dose, which did not show a dose–response pattern. However, in the case of CP, only the high
dose was effective. Additive effects were observed when both products were combined at the lowest
doses used (W 1 µg/mL + CP 50 µg/mL). By contrast, in the case of the highest doses, no additive
or synergistic effects were observed when combined extracts of both products were included in the
incubation medium, because their effects were not greater than those induced by CP. These results
revealed that with regard to TG reduction, a 1/50 ratio of W/CP, but not 1/5, reached a similar level
of decrease (−36%) to that observed in previous studies with W 100 µg/mL (−38%) [17]. As stated
in the introduction, one of the most important limitations for functional snack formulation is the
dose used. According to the results obtained, W 1 µg/mL + CP 50 µg/mL in vitro treatment was
enough to raise the maximum TG-lowering effect. It has been demonstrated that phenolic compounds
undergo extensive metabolism after oral ingestion, thus notably reducing their bioavailability, and that
only a small amount of them reaches plasma and tissues [25]. This fact, as stated by Langhans in the
review about food components in health promotion and disease prevention [26], makes it difficult
to extrapolate the positive effects observed in vitro, usually carried out at supraphysiological doses.
Therefore, the effective combination of W+CP at low doses (1 and 50 µg/mL, respectively) makes it
easier to extrapolate possible uses of these compounds in in vivo studies or in clinical practice.
In order to explain the mechanisms underlying the delipidating effect, the expressions of genes
involved in the main metabolic processes of adipocyte triglyceride metabolism were measured in
adipocytes cultured with W 1 µg/mL + CP 50 µg/mL. No significant changes were observed in the
expression of genes codifying for enzymes involved in lipolysis (hormone sensitive lipase and adipose
triglyceride lipase, lipe and pnpla respectively). As far as lipogenic genes are concerned, acca and
stearoyl-Coenzyme A desaturase 1 (scd1) remained unchanged, but fasn showed a tendency toward a
reduction. In view of these results, and considering that one of the most active molecules in W, namely
fucoxanthin, has been proposed as an antilipogenic molecule [27], we analyzed the protein expression
and activity of FAS, and the activity of ACC by measuring the ratio phosphorylated ACC/total
ACC, but no changes were observed. Similarly, in order to know whether lipolysis was affected at
post-transcriptional level, the amount of glycerol released to the incubation medium was measured,
but no significant differences were found. Therefore, it seems that de novo lipogenesis and lipolysis
metabolic processes were not involved in the delipidating effect of the analyzed combination.
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Moreover, a significant decrease was observed in dgat2, and the gene codifying for GLUT4
transporter (scl2a4) was not detected. These results showed that the assembly of triglycerides was
impaired, not only due to decreases in the activity of a key enzyme of this metabolic process, but also
due to the limited availability of glycerol-3P coming from glucose metabolism. Finally, the combination
increased the expression of the pro-apoptotic gene bax and maintained that of the anti-apoptotic gene
bcl2, showing that increased apoptosis also contributed to the reduction in total TG accumulated
in adipocytes.
Even though the W functional ingredient was enough to promote the TG-lowering effect,
it poses a clear limitation with regard to combatting the inflammation. In order to overcome this
handicap, CP was also evaluated in the present study. In vitro assays demonstrated that the most
clear anti-inflammatory action was found in macrophages treated with CP. It has been proposed
that the compounds responsible for this action, by means of their anti-oxidant effects, are phenolic
compounds [28], with phenolic acids, gallotannins, and flavonoids being the most significant [19].
As in the case of TG-lowering effect, no additive or synergistic was observed with the combination of
CP and W. Nevertheless, taken together the cell culture results demonstrated that the combination of
W with CP represents a more complete formulation that is useful for MetS treatment.
The positive results obtained in the in vitro study encouraged us to address an in vivo study.
In this experiment, rats were fed a high-fat high-sucrose diet in order to induce MetS, and then they
were treated with two snacks elaborated with W and CP in different proportions, as described in
the Material and Methods section. The high-dose snack diets evaluated the effect of the complete
substitution of complex carbohydrates using functional snacks [29], and the low-dose snack diet
simulated a human intervention study, with an affordable functional snack intake (50 g per day, in a
total contribution of complex carbohydrates of 250 g) [30]. Surprisingly, the expected anti-obesity effect
was not observed because no reductions were found in WAT weights among experimental groups.
Although no differences were observed by comparing experimental groups (SAL, SAH, and SBH) with
control groups (OC and WC) in terms of energy intake, overall modification of energy expenditure (EE)
by treatment cannot be discarded. Some authors have postulated the use of poly(phenols) as a strategy
for weight loss, as they can increase EE [31]. In this line, it is important to highlight that W and CP are a
good source of these compounds. Similarly to phenolic compounds, fucoxanthin carotenoid, included
in W, also increases EE [32]. Unfortunately, an indirect calorimetry was not addressed in the present
research, implying a limitation of the study. Wu et al. demonstrated that fucoxanthin supplementation
to high-fat or high-sucrose diets at 0.2% activated proliferator-activated receptor-gamma coactivator
1-α cascade and mitochondrial fusion, leading to the activation of mitochondrial biogenesis, and a
thermogenic program [33]. Among others, they observed an increase in the nuclear respiratory factor-1
(Nrf1) gene expression in epididymal white adipose tissue, as well as a strong decrease in the size of
this fat depot. Recently, Nrf1 was proposed in thermogenic fat cells as a metabolic guardian, avoiding
tissue stress and inflammation independently of BAT differentiation, mass or expandability [34].
In addition, in a previous study we revealed that Ilex paraguariensis, rich in phenolic compounds,
increased mitochondriogenesis and energy dissipation in brown adipose tissue and skeletal muscle,
which explained the mass change of these oxidative tissues [35]. However, taking into account the
lack of change in brown adipose tissue and gastrocnemius weights, and even more, in white adipose
weights, it seems that under our experimental conditions, there was no sharp EE modification.
As far as the anti-inflammatory effect is concerned, no changes were found in the serum
concentration of CRP. In the case of MCP1 and IL6, although serum concentrations were significantly
reduced in rats fed the diets supplemented with the combination of W and CP when compared
the MetS group, no significant changes were observed with rats fed the OC diet. Notwithstanding,
a tendency toward a decrease was observed for the SAH rat group, which could become significant
in a longer treatment. Effect of snack feeding on glycemic control was also evaluated. Although no
clear improvement of glycemic control was found in rats treated with snack, lower NEFA values were
detected for SAL, SAH, and SBH rat groups than MetS rats.
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In addition, other parameters altered in MetS were also analyzed. After three weeks of treatment,
the high dose of snack A reduced SBP. When we measured the activity of ACE, the enzyme that
converts angiotensin I into angiotensin II, thus, increasing vasoconstriction, a reduction was observed
in the SHA group, but only when it was compared with the OC group, not with the WC group.
The SHB group showed a great increase. According to these results, which do not fit well with an
anti-hypertensive action, it can be proposed that other mechanisms, not analyzed in the present work,
are the basis for this effect. These results are in good accordance with those reported by Park et al. [36].
These authors observed a reduction in blood pressure in hypertensive rats induced via fucoidan
obtained from W. This effect was due to increased eNOS activation by Akt phosphorylation, and
thus increased NO production, to increased endothelium-dependent vasodilation, and to improved
vascular elasticity.
We cannot state, given the amount of W and CP included in the snacks, that the amounts of
their bioactive components reaching the cells are high enough to be effective, because unfortunately,
no kinetic studies are available. This may be one of the reasons that explain the lack of anti-obesity
and anti-inflammatory effects observed in MetS rats. Likewise, potential interactions among diet
components can take place. Moreover, the thermal treatment needed to prepare the snacks can
negatively affect the bioavailability and activity of CP and W bioactive components.
Our results cannot be compared with other studies because the snacks used in the present study
have not been used previously. With regard to CP, no information is available concerning its potential
effect on body fat. Nevertheless, we can consider reported studies carried out with W. In some of
them, the algae showed an anti-obesity effect. In this sense, Park et al. (2011) observed a significant
reduction in epididymal adipose tissue and adipocyte size in mice fed a high-fat diet supplemented
with W [37]. According to this result and our in vitro data, an anti-obesity effect should have been
found in our experiment in rats treated with the snacks. This apparent discrepancy could be due to the
fact that mice have a faster TG metabolism in WAT than rats. However, this hypothesis is refuted by
two facts. There are also studies in the literature that show reduced body weight and WAT weights in
rats, and there are also reported results showing no anti-obesity effects in mice [21].
One might also consider the experimental period length, which was longer in the study reported
by Park et al. (9 weeks) than in the present study (4 weeks) [37]. Giving support to this idea,
Grasa-López et al. [15] reported decreases in WAT weight and adipocyte size in rats fed a high-fat diet
supplemented with W at a dose of 400 mg/kg body weight for 8 weeks, as well as a reduction in serum
inflammatory markers and blood pressure. Nevertheless, Kim et al. (2016) also showed a reduction
in WAT weights by using W at concentrations from 0.6% to 1.7% (approximately 320 and 900 mg
extract/kg body weight) during a shorter experimental period (5 weeks) [16]; consequently, it seems
that this factor does not explain the discrepancy. It is important to point out that in the study reported
by Kim et al., a reduction in energy intake, which should be related to a smaller WAT, was found, but a
pair-fed group was not used in order to discard this confounding factor. The amounts of W used in
the studies can also represent a differential factor. Regarding this issue, it should be emphasized that
the amounts used in our study were lower (5–200 mg/kg body weight/day) than those used in the
reported studies (320–900 mg/kg body weight/day). Due to the fact that our study, carried out in rats,
was prior to a clinical intervention study that is now ongoing, we chose the doses of W to be included
in the snack based on a sensory panel.
Another aspect related to the experimental design that should also be considered is that, in the
above-mentioned studies, W was administered at the same time as the obesogenic diet; and thus the
preventive effect of this algae was analyzed. By contrast, in our study, the snack containing W was
included in the diet after inducing the MetS, and thus the treatment of this syndrome was assessed.
This situation is not unique to W, it has also been observed by using, for instance, resveratrol. When the
anti-obesity of this phenolic compound is analyzed, it can be observed that it is able to prevent fat
accumulation associated to obesogenic diets, but not to reduce it when obesity has been previously
established, or to increase fat reduction when it is administered in the frame of a hypocaloric diet [38].
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Finally, it is important to point out that bearing in mind that final consumers for this type of snack
would be adults, in our study adult rats were used. This fact differed from the majority of previous
in vivo treatments, which were conducted with growing animals.
4. Materials and Methods
4.1. Ethical Approval
The animal experiment was approved in accordance with the Spanish regulation on animal
experimentation (approval no M20_2017_003). All experimental protocols were reviewed and approved
by the ethics committee on animal welfare of our institution (Comité Ético de Experimentación Animal
de la Universidad del País Vasco, CEEA-UPV/EHU).
4.2. Reagents
Dimethyl sulfoxide, LPS from Escherichia coli O5:B55, penicillin/streptomycin (10,000 U/mL),
and captopril were purchased from Sigma-Aldrich (St. Louis, MO, USA). Dulbecco’s modified
Eagle’s medium (DMEM) was purchased from GIBCO (BRL Life Technologies, Grand Island, NY,
USA). All other chemicals were obtained from Panreac Química S.A (Barcelona, Spain) unless
otherwise stated.
4.3. Raw Material
CP was provided by Alimentaria Adín (Paterna, Valencia, Spain) and W seaweed was harvest
and provided by Portomuiños (Galicia, Spain). Fresh raw materials were lyophilized and powdered
via grinding and kept at −80 ◦C for further analysis.
4.4. Carob Pod and Wakame Extract Preparation
One gram of powdered W and CP was homogenized in 2 × 10 mL of 50% aqueous methanol via
magnetic stirring for 1 h, and then centrifuged at 1635× g for 10 min at 4 ◦C. Supernatants of both
methanolic extracts were mixed and filtered with filter paper (Whatman Grade 1). Using reduced
pressure (SpeedVac Concentrator, Thermo Fisher Scientific Inc., Rockford, IL, USA) the obtained
filtrates were evaporated and stored at −80 ◦C until analysis.
Methanolic extracts were used to evaluate bioactive properties, due to the fact that methanol has
a higher dielectric constant than ethanol, which enables it to extract more polar (phenolic) compounds
than ethanol.
4.5. In Vitro Assays: Anti-Hypertensive, Triacylglycerol-Lowering, and Anti-Inflammatory Activities
In order to conduct the ACE inhibitory activity, the method described by Shalaby et al. (2006) [39].
The fluorescence from release of Abz-Gly was determined at time zero by a microplate reader with
excitation and emission wavelengths of 360 nm and 400 nm, respectively. Then, the assay plate was
incubated at 37 ◦C for 30 min and the fluorescence was determined again. The obtained IC50 values
were corrected for moisture and expressed as a gram of sample per liter of medium present during the
reaction (g/L). The antihypertensive activity of captopril was used as a control of ACE inhibitor to
evaluate the assay reproducibility. Experiments were carried out as independent duplicates assayed
in triplicate.
3T3-L1 pre-adipocytes, supplied by American Type Culture Collection (Manassas, VA, USA) were
cultured and stimulated to differentiate as previously reported [40]. From day 2 after differentiation,
the medium contained fetal bovine serum /DMEM (10%) with 0.2 µg/mL insulin. This medium
was changed every two days until the cell treatment (day 8). At day 8, >90% of cells developed
mature adipocytes with visible lipid droplets. All medium contained 1% penicillin/streptomycin
(10,000 U/mL), and the medium for differentiation and maturation contained 1% (v/v) of biotin and
panthothenic acid. Cells were maintained at 37 ◦C in a humidified 5% CO2 atmosphere. For the
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treatment of mature adipocytes, first of all, preparation of extracts was carried out. W and CP
methanolic extracts were dried in a vacuum concentrator (Speedvac, Eppendorf, Madrid, Spain),
and subsequently, the dry weight was registered. For cell treatment, W and CP dry extracts were
dissolved first in 95% ethanol and then in the treatment medium to prepare W (1 or 10 µg/mL) and
CP (50 or 100 µg/mL) test solutions. The ethanol concentration in the medium never exceeded 0.1%.
Cells grown in six-well plates were in expenditure cubated with either ethanol (control group) or
with W, CP, and their combination at 1, 10, 50, and 100 µg/mL (diluted 95% ethanol) on day 8 after
differentiation. The treatment medium contained only fetal bovine serum /DMEM (10%). After 24 h,
the supernatant was collected, and cells were used for TG determination (Thermo Fisher Scientific
Inc., Rockford, IL, USA) and glycerol quantification in the medium (Sigma, St. Louis, MO, USA) as
described elsewhere [40]. Each experiment was performed three times.
The RAW 264.7 cell line (American Type Culture Collection, Rockville, MD, USA) from a mouse
monocyte macrophage was used to study the anti-inflammatory activity of W, CP, or their combination.
Cells were seeded in 96-well plates at a density of 2 × 104 cells/well and maintained in DMEM
supplemented with 10% FBS, and 1% penicillin/streptomycin in a humidified incubator containing 5%
CO2 and 95% air at 37 ◦C as previously reported [17]. On the day before the assay, cells (80% confluent)
were changed to an FBS-free medium to avoid potential interference of the serum. Dried W and CP
extracts were dissolved in an FBS-free medium to prepare the W and CP test solutions. Cells were
treated with W (1 or 10 µg/mL), CP (50 or 100 µg/mL), or their combination (W 10 µg/mL + CP
50 µg/mL, W 1 µg/mL + CP 50 µg/mL) for 24 h and sequentially elicited with 10 µg/mL of LPS
from Escherichia coli O55:B5 for an additional period of 24 h. Cell treatments were performed in
sextuplicate. Control wells, with cells in a culture medium without W and CP or LPS, were also
included to observe potential effects of LPS elicitation and W and CP treatment. Finally, the medium
was collected and NO production was quantified using the Griess reaction, following a previously
described method [41]. Similarly, TNFα and PGD2 detection were carried out in the medium using
a sandwich enzyme-linked immunosorbent assay (ELISA) (Diaclone SAS, Besancon Cedex, France,
and Cayman Chemical, Ann Arbor, MI, USA).
4.6. RNA Extraction and Reverse Transcription Polymerase Chain Reaction (RT-PCR)
RNA samples from mature adipocytes and macrophages were extracted using Trizol (Invitrogen,
Carlsbad, CA, USA), according to the manufacturer’s instructions. After RNA purity verification,
samples were then treated with DNase I kit (Applied Biosystems, Foster City, CA, USA) to remove any
contamination with genomic DNA. A total of 1.5 µg of RNA of each sample was reverse-transcribed to
first-strand complementary DNA (cDNA) using iScriptTM cDNA Synthesis Kit (Bio-Rad, Hercules,
CA, USA).
Relative mRNA levels of genes in adipocytes, as well as macrophages, were quantified using
SYBR Green Master Mix or TaqMan® Fast Advanced Master Mix (Applied Biosystems, Foster City,
CA, USA) using Real-Time PCR with an CFX96 real-time PCR detection system (BioRad, Hercules,
CA, USA). The sense/antisense primers (Metabion International AG, Steinkirchen, Germany) and
annealing temperature in the case of SYBR Green RT-PCR are listed in Table 2. For Taqman
technology, the following TaqMan® Gene Expression Assays were used (Applied Biosystems,
Foster City, CA, USA): acca, (mm01304285_m1); fasn (m00662319_m1); pnpla2 (mm00503040_m1);
lipe (mm00495359_m1); slc2a4 (mm00436615_m1); dgat1 (mm00515643_m1); and dgat2 (mm499536_m1).
The RT-PCR parameters used were those defined by manufacturers, with the exception of slc42a.
In that case, RT-PCR consisted of fifty cycles of denaturation/annealing/extension. β-actin was used
as the reference gene. All gene expression results were expressed as fold changes of the threshold cycle
(Ct) value relative to controls using the 2−∆∆Ct method [42].
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Table 2. Primers for PCR amplification of each gene studied.
Primers Sense Primer Antisense Primer Ref. AnnealingT(◦C)
β-actin 5′-ACG AGG CCC AGA GCA AGA G-3′ 5′-GGT GTG GTG CCA GAT CTT CTC-3′ 60.0
bax 5′-GTG AGC GGC TGC TTG TCT-3′ 5′-GTG GGG GTC CCG AAG TAG-3′ 59.0
bcl2 5′-AGT ACC TGA ACC GGC ATC TG-3′ 5′-GGG GCC ATA TAG TTC CAC AAA-3′ 59.0
cox2 5′-GCT ACC TGG AGT ACA TGA AG-3′ 5′-CTG TGA CTC CAG CTT ATC TG-3′ [43] 57.3
il6 5′-GCT ACC TGG AGT ACA TGA AG-3′ 5′-GCA TAA CGC ACT AGG TTT GCC-3′ [44] 60.0
nos2 5′-CTT TGC CAC GGA CGA GAC-3′ 5′-TCA TTG TAC TCT GAG GGC TGA C-3′ 63.7
scd1 5′-TTC TTG CGA TAC ACT CTG GTG C-3′ 5′-CGG GAT TGA ATG TTC TTG TCG T-3′ [45] 64.5
tnfa 5′-TCA CCT GCT GCT ACT CAT TC-3′ 5′-TAC AGA AGT GCT TGA GGT GG-3′ [43] 62.7
bax, BCL2-associated X protein; bcl2, B cell leukemia/lymphoma 2; cox2, cyclooxygenase 2; il6, interleukin 6; nos2;
nitric oxide synthase 2; scd1, stearoyl-Coenzyme A desaturase 1; tnfα, tumor necrosis factor α.
4.7. Western Blot Analysis
Total protein was isolated from maturing 3T3-L1 adipocytes using 150 µL of lysis buffer (2 nM
tris-HCl, 0.1 M sodium chloride, 1% Triton, 10% glycerol, 1 mM sodium orthovanadate, 2 mM EDTA,
1 mM phenylmethylsulfonyl fluoride, 2 mM sodium fluoride, and 1% protease inhibitor) and centrifuged
(12,000× g, 15 min, 4 ◦C) to remove membranes and other proteic residues. Protein concentration
was determined using a BCA protein assay kit (Thermo Fisher Scientific Inc., Rockford, IL, USA).
Sixty micrograms of protein were subjected to 10% SDS polyacrylamide gel, electroblotted onto PVDF
membranes (Merck KGaA, Darmstadt, Germany), and incubated with specific antibodies for FAS
(1:250), β-actin (1:5000) (Santa-Cruz Biotech, Dallas, TX, USA) and Acetyl-CoA carboxylase enzyme
(ACC; (1:1000) (Cell Signaling Technology, Danvers, MA, USA) overnight. Subsequently, polyclonal
anti-mouse for β-actin and FAS, and anti-rabbit for ACC (1:5000) (Santa-Cruz Biotech, Dallas, TX, USA)
were incubated for 2 h at room temperature, and FAS, ACC, and β-actin were measured. After antibody
stripping, the membranes were blocked, and then incubated with phosphorylated ACC (serine 79,
1:1000) (Cell Signaling Technology, Danvers, MA, USA) antibodies. Bound antibodies were visualized
by an ECL system (Thermo Fisher Scientific Inc., Rockford, IL, USA) and quantified using a Chemi-Doc
MP imaging system (Bio-Rad, Hercules, CA, USA).
4.8. Fatty Acid Synthase Activity
FAS activity was measured with 75 µL of protein from a mature adipocyte homogenate using
a spectrophotometer (Thermo Fisher Scientific Inc., Rockford, IL, USA) at 340 nm as previously
reported [40].
4.9. Snack Preparation
A yeasted cracker based on a carob-seaweed-flour blend was formulated according to preliminary
studies [17,24]. Dough samples were prepared by mixing baker’s yeast (0.48%), wheat (24.1%), oat
(24.1%), CP (5.29% for snack A and 4.49% for snack B), and W flour (0.105% for snack A and 0.898% for
snack B), carboxymethyl cellulose (0.289%), and extra olive oil (7.22%). Additional water was added as
required to obtain easily handled doughs (38.5%). After mixing all ingredients for 5 min, the dough
was allowed to rest at room temperature for 10 min and subsequently incubated for 40 min at 37 ◦C to
allow the fermentation process to take place. Then, the doughs were laminated into a 2 mm thickness
layer, cut into crackers (900 × 400 mm), and transferred to a baking sheet. Each batch was baked in a
forced-air convection oven at 200 ◦C for 10 to 12 min. The final snack formulations were packed in
modified atmosphere bags and stored at room temperature for the study. Protein, fat, moisture, ash,
fiber, and carbohydrate contents were determined as detailed in Martín-Diana et al. [46]. Data were
expressed as % of dry weight basis (d.w.b.).
4.10. Animals and Treatment Protocols
The experiment was conducted with 60 six-week-old male Wistar RccHan rats (203 ± 2.5 g)
from Envigo (Barcelona, Spain). The rats were individually housed in polycarbonate metabolic cages
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(Tecniplast Gazzada, Buguggiate, Italy) and placed in an air-conditioned room (22 ± 2 ◦C) with a
12-h light–dark cycle. After a 6-day adaptation period, all rats were fed a high-fat, high-fructose diet
(Brogardeen, Lynge, Denmark; Ref. D09100301) for eight weeks in order to develop MetS. This diet
provided 40% of the energy as fat, 20% as protein, and 40% as carbohydrates where 20% was fructose
(4.5 kcal/g diet). After this period, in order to establish the MetS baseline parameters, 10 fourteen-week
old rats (MetS group) were sacrificed. The remaining 50 animals, fed a semi-purified, normal-caloric
diet (3.9 kcal/g diet) for four weeks, were randomly divided into five experimental groups (b = 10):
WC, OC, SAL, SAH, and SBH. The composition of each powder diet is described in Table 3. The WC
diet represented the standard normal-caloric diet for the treatment of MetS in humans. It was prepared
according to previous studies from our laboratory with adult rodents, as well as recommendations
from the American Institute of Nutrition (AIN-93M) [47]. Considering that oat flour was highly present
in the snack formulation, at the same level as wheat flour, starch for the OC diet came from oat and
wheat flour in similar amounts. High-dose snack dietary interventions evaluated the effect of the
complete substitution of complex carbohydrates with functional snacks [29]. The low-dose snack diet
simulated a human intervention study, with an attainable functional snack intake (50 g per day, in a
total contribution of complex carbohydrates of 250 g) [30].
At the end of the whole experimental period (8+4 weeks), eighteen-week old rats from the
five experimental groups were sacrificed after 8–12 h of fasting, under anesthesia (chloral hydrate),
via cardiac exsanguination. Serum was obtained from blood samples after centrifugation (1000 g
for 10 min at 4 ◦C). Gastrocnemius muscle, IBAT, and WAT from different anatomical locations
(epididymal, perirenal, mesenteric, and subcutaneous) were dissected, weighed, and immediately
frozen. All samples were stored at −80 ◦C until further analysis.
4.11. Anti-Hypertensive, Anti-Inflammatory, and Glycemic Control Improvement Properties Evaluation of
Functional Snack in MetS Rats
Blood pressure was recorded at the beginning and one week before the sacrifice, with the exception
of the MetS group, whose blood pressure was measured at the end of the eight-week period used for
MetS induction. SBP and DBP were recorded between 9 and 11 a.m. in rats using a non-invasive blood
pressure system (LE50002, Panlab Harvard Apparatus, Barcelona, Spain). To minimize stress-induced
variations in BP, all measurements were taken by the same person in the same peaceful environment
and after acclimatizing animals to the procedure.
Table 3. Diet composition and suppliers.
Ingredients WC (g/kg) OC (g/kg) SAL (g/kg) SAH (g/kg) SBH (g/kg)
Casein 1 200 200 200 200 200
Sucrose 2 230 230 230 230 230
Wheat starch 3 400 200 320 - -
Oat starch 3 - 200 - - -
Snack A - - 80 400 -
Snack B - - - - 400
Sunflower oil 2 70 70 70 70 70
Cellulose 3 46 46 46 46 46
Mineral mix 4 35 35 35 35 35
Vitamin mix 4 11 11 11 11 11
L-methionine 1 4 4 4 4 4
Choline chlorhydrate 1 4 4 4 4 4
WC: wheat control group; OC: wheat-oat control group; SAL: the snack A low-dose group; SAH: snack A high-dose
group; SBH: snack B high-dose group; 1 Sigma, St. Louis, MO, USA; 2 Local market; 3 Vencasser, Bilbao, Spain;
4 ICN Pharmaceuticals, Costa Mesa, CA, USA.
ACE activity was measured in the kidney by using a commercial kit (Spinreact, Girona, Spain). Briefly,
0.1 g of the right kidney was quickly homogenized in 2 mL of 50 mM Tris-HCl buffer, pH 7.4, containing
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0.1% NaCl. Homogenates were centrifuged at 1000× g for 15 min at 4 ◦C and the supernatant was
frozen at −20 ◦C. The protein contents of the samples were measured using the BCA method.
Specific rat ELISA kits were used for CRP (Biovendor, Brno, Czech Republic), monocyte chemotactic
protein 1 (MCP1) (Thermo Fisher Scientific Inc., Rockford, IL, USA), interleukin-6 (IL6) (R&D Systems,
Minneapolis, MN, USA) and insulin (Merck KGaA, Darmstadt, Germany) measurements in serum
samples at the end of the experimental period. Glucose and NEFAs were measured using a commercially
available spectrophotometer (Biosystems, Barcelona, Spain).
4.12. Statistical Analysis
Results were presented as mean ± standard error of the mean (SEM). After confirming the normal
distribution of variables, differences among groups were determined using the Student’s t-test for the
comparison of two groups or one-way analysis of variance (ANOVA), following Bonferroni’s multiple
comparison using SPSS 24.0 software (SPSS Inc., Chicago, IL, USA). Statistical significance was defined
as p < 0.05).
5. Conclusions
Taken as a whole, these results show that both W and CP show TG-lowering effects, but only
the latter induced additional anti-inflammatory and anti-hypertensive actions. The combination of
both components did not induce an additive or synergistic delipidating in vitro effect. As far as the
in vivo study is concerned, snack B was ineffective, while snack A showed an anti-hypertensive effect
in rats with MetS. However, the effects observed cannot be extrapolated to humans because this effect
was only found with the highest dose, and so intervention studies should be addressed. Furthermore,
due to the fact that statistical tendencies were observed in several parameters, further studies would
be necessary to elucidate whether longer treatment periods could induce significant anti-obesity and
anti-inflammatory effects.
Author Contributions: Data curation, C.M.-V., E.P., D.R., A.B.M.-D., and J.M.; Formal analysis, C.M.-V., D.R.,
A.B.M.-D., and J.M.; Investigation, C.M.-V., D.R., and J.M.; Methodology, C.M.-V., M.T.M., D.A.d.L., and J.M.;
Writing—original draft, M.P.P.; Writing—review and editing, J.M.
Funding: This study has been supported by the National Institute for Agricultural and Food Research and
Technology of Spain (INIA: RTA2014-0037-C02), University of the Basque Country (ELDUNANOTEK UFI11/32),
Instituto de Salud Carlos III (CIBERobn), and the Basque Government (IT-572-13).
Acknowledgments: The authors would like to thank to Adín Alimentaria and Portomuiños for kindly supplying
raw material, and to the Ministerio de Ciencia, Innovación y Universidades (MCIU).
Conflicts of Interest: The authors declare no conflict of interest.
References
1. Saklayen, M.G. The global epidemic of the metabolic syndrome. Curr. Hypertens. Rep. 2018, 20, 12. [CrossRef]
2. National Cholesterol Education Program (NCEP) Expert Panel on Detection, E.a., and Treatment of High
Blood Cholesterol in Adults (Adult Treatment Panel III). Third report of the national cholesterol education
program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults
(adult treatment panel III) final report. Circulation 2002, 106, 3143–3421. [CrossRef]
3. Hosseini, Z.; Whiting, S.J.; Vatanparast, H. Current evidence on the association of the metabolic syndrome
and dietary patterns in a global perspective. Nutr. Res. Rev. 2016, 29, 152–162. [CrossRef] [PubMed]
4. Monteiro, R.; Azevedo, I. Chronic inflammation in obesity and the metabolic syndrome. Mediat. Inflamm.
2010, 2010. [CrossRef] [PubMed]
5. Arner, P. The adipocyte in insulin resistance: Key molecules and the impact of the thiazolidinediones. Trends
Endocrinol. Metab. 2003, 14, 137–145. [CrossRef]
6. Rutkowski, J.M.; Stern, J.H.; Scherer, P.E. The cell biology of fat expansion. J. Cell Biol. 2015, 208, 501.
[CrossRef] [PubMed]
Mar. Drugs 2018, 16, 512 16 of 18
7. Pucci, A.; Finer, N. New medications for treatment of obesity: Metabolic and cardiovascular effects. Can. J.
Cardiol. 2015, 31, 142–152. [CrossRef] [PubMed]
8. Amiot, M.J.; Riva, C.; Vinet, A. Effects of dietary polyphenols on metabolic syndrome features in humans:
A systematic review. Obesity Reviews 2016, 17, 573–586. [CrossRef] [PubMed]
9. Governa, P.; Baini, G.; Borgonetti, V.; Cettolin, G.; Giachetti, D.; Magnano, R.A.; Miraldi, E.; Biagi, M.
Phytotherapy in the management of diabetes: A review. Molecules 2018, 23, 105. [CrossRef]
10. Wan-Loy, C.; Siew-Moi, P. Marine algae as a potential source for anti-obesity agents. Mar. Drugs 2016, 14, 222.
[CrossRef] [PubMed]
11. Fung, A.; Hamid, N.; Lu, J. Fucoxanthin content and antioxidant properties of Undaria pinnatifida. Food Chem.
2013, 136, 1055–1062. [CrossRef]
12. Billakanti, J.M.; Catchpole, O.J.; Fenton, T.A.; Mitchell, K.A.; MacKenzie, A.D. Enzyme-assisted extraction
of fucoxanthin and lipids containing polyunsaturated fatty acids from Undaria pinnatifida using dimethyl
ether and ethanol. Process Biochem. 2013, 48, 1999–2008. [CrossRef]
13. Sánchez-Machado, D.I.; López-Hernández, J.; Paseiro-Losada, P.; López-Cervantes, J. An HPLC method for
the quantification of sterols in edible seaweeds. Biomed. Chromatogr. 2004, 18, 183–190. [CrossRef] [PubMed]
14. Suetsuna, K.; Nakano, T. Identification of an antihypertensive peptide from peptic digest of wakame (Undaria
pinnatifida). J. Nutr. Biochem. 2000, 11, 450–454. [CrossRef]
15. Grasa-López, A.; Miliar-García, Á.; Quevedo-Corona, L.; Paniagua-Castro, N.; Escalona-Cardoso, G.;
Reyes-Maldonado, E.; Jaramillo-Flores, M.E. Undaria pinnatifida and fucoxanthin ameliorate lipogenesis
and markers of both inflammation and cardiovascular dysfunction in an animal model of diet-induced
obesity. Mar. Drugs 2016, 14, 148. [CrossRef]
16. Kim, B.-M.; Park, J.-H.; Kim, D.-S.; Kim, Y.-M.; Jun, J.-Y.; Jeong, I.-H.; Chi, Y.-M. Effects of the polysaccharide
from the sporophyll of brown alga Undaria Pinnatifida on serum lipid profile and fat tissue accumulation in
rats fed a high-fat diet. J. Food Sci. 2016, 81, H1840–H1845. [CrossRef]
17. Rico, D.; Diana, A.B.M.; Milton-Laskibar, I.; Fernández-Quintela, A.; Silván, J.M.; Rai, D.K.; Choudhary, A.;
Peñas, E.; de Luis, D.A.; Martínez-Villaluenga, C. Characterization and in vitro evaluation of seaweed species
as potential functional ingredients to ameliorate metabolic syndrome. J. Funct. Foods 2018, 46, 185–194.
[CrossRef]
18. Clark, L.J.; Taylor, G.C.; Zahradka, P. Rebelling against the (Insulin) resistance: A review of the proposed
insulin-sensitizing actions of soybeans, chickpeas, and their bioactive compounds. Nutrients 2018, 10, 434.
[CrossRef]
19. Goulas, V.; Stylos, E.; Chatziathanasiadou, V.M.; Mavromoustakos, T.; Tzakos, G.A. Functional components
of carob fruit: Linking the chemical and biological space. Int. J. Mol. Sci. 2016, 17, 1875. [CrossRef]
20. Papagiannopoulos, M.; Wollseifen, H.R.; Mellenthin, A.; Haber, B.; Galensa, R. Identification and quantification
of polyphenols in carob fruits (Ceratonia siliqua L.) and derived products by HPLC-UV-ESI/MSn. J. Agric. Food
Chem. 2004, 52, 3784–3791. [CrossRef]
21. Oh, J.H.; Kim, J.; Lee, Y. Anti-inflammatory and anti-diabetic effects of brown seaweeds in high-fat
diet-induced obese mice. Nutr. Res. Pract. 2016, 10, 42–48. [CrossRef] [PubMed]
22. Braithwaite, M.C.; Tyagi, C.; Tomar, L.K.; Kumar, P.; Choonara, Y.E.; Pillay, V. Nutraceutical-based
therapeutics and formulation strategies augmenting their efficiency to complement modern medicine:
An overview. J. Funct. Foods 2014, 6, 82–99. [CrossRef]
23. Dandona, P.; Aljada, A.; Chaudhuri, A.; Mohanty, P.; Garg, R. Metabolic syndrome: A comprehensive
perspective based on interactions between obesity, diabetes, and inflammation. Circulation 2005, 111,
1448–1454. [CrossRef] [PubMed]
24. Rico, D.; Alonso-De Linaje, A.; Herrero, A.; Asensio-Vegas, C.; Miranda, J.; Martínez-Villaluenga, C.;
De Luis, D.A.; Martin-Diana, A.B. Carob by-products and seaweeds for the development of functional bread.
J. Food Process. Preserv. 2018, 42. [CrossRef]
25. Scalbert, A.; Williamson, G. Dietary intake and bioavailability of polyphenols. J. Nutr. 2000, 130, 2073S–2085S.
[CrossRef] [PubMed]
26. Langhans, W. Food components in health promotion and disease prevention. J. Agric. Food Chem. 2018, 66,
2287–2294. [CrossRef]
27. Zhang, H.; Tang, Y.; Zhang, Y.; Zhang, S.; Qu, J.; Wang, X.; Kong, R.; Han, C.; Liu, Z. Fucoxanthin: A promising
medicinal and nutritional ingredient. Evid. Based Complement. Alternat. Med. 2015, 2015, 723515. [CrossRef]
Mar. Drugs 2018, 16, 512 17 of 18
28. Ydjedd, S.; Bouriche, S.; López-Nicolás, R.; Sánchez-Moya, T.; Frontela-Saseta, C.; Ros-Berruezo, G.; Rezgui, F.;
Louaileche, H.; Kati, D.E. Effect of in vitro gastrointestinal digestion on encapsulated and nonencapsulated
phenolic compounds of carob (Ceratonia siliqua L.) pulp extracts and their antioxidant capacity. J. Agric. Food
Chem. 2017, 65, 827–835. [CrossRef]
29. Bajerska, J.; Chmurzynska, A.; Mildner-Szkudlarz, S.; Drzymała-Czyz˙, S. Effect of rye bread enriched with
tomato pomace on fat absorption and lipid metabolism in rats fed a high-fat diet. J. Sci. Food Agric. 2015, 95,
1918–1924. [CrossRef]
30. Paturi, G.; Butts, C.A.; Bentley-Hewitt, K.L.; Ansell, J. Influence of green and gold kiwifruit on indices of
large bowel function in healthy rats. J. Food Sci. 2014, 79, H1611–H1620. [CrossRef]
31. Mele, L.; Bidault, G.; Mena, P.; Crozier, A.; Brighenti, F.; Vidal-Puig, A.; Del Rio, D. Dietary (Poly)phenols,
brown adipose tissue activation, and energy expenditure: A narrative review. Adv. Nutr. 2017, 8, 694–704.
[CrossRef] [PubMed]
32. Gammone, M.A.; D’Orazio, N. Anti-obesity activity of the marine carotenoid fucoxanthin. Mar. Drugs 2015,
13, 2196–2214. [CrossRef] [PubMed]
33. Wu, M.T.; Chou, H.N.; Huang, C.J. Dietary fucoxanthin increases metabolic rate and upregulated mRNA
expressions of the PGC-1alpha network, mitochondrial biogenesis and fusion genes in white adipose tissues
of mice. Mar. Drugs 2014, 12, 964–982. [CrossRef] [PubMed]
34. Bartelt, A.; Widenmaier, S.B.; Schlein, C.; Johann, K.; Goncalves, R.L.S.; Eguchi, K.; Fischer, A.W.;
Parlakgül, G.; Snyder, N.A.; Nguyen, T.B.; et al. Brown adipose tissue thermogenic adaptation requires
Nrf1-mediated proteasomal activity. Nat. Med. 2018, 24, 292–303. [CrossRef] [PubMed]
35. Dos Santos, T.W.; Miranda, J.; Teixeira, L.; Aiastui, A.; Matheu, A.; Gambero, A.; Portillo, M.P.; Ribeiro, M.L.
Yerba mate stimulates mitochondrial biogenesis and thermogenesis in high-fat-diet-induced obese mice.
Mol. Nutr. Food Res. 2018, e1800142. [CrossRef] [PubMed]
36. Li, X.; Li, J.; Li, Z.; Sang, Y.; Niu, Y.; Zhang, Q.; Ding, H.; Yin, S. Fucoidan from Undaria pinnatifida
prevents vascular dysfunction through PI3K/Akt/eNOS-dependent mechanisms in the l-NAME-induced
hypertensive rat model. Food Funct. 2016, 7, 2398–2408. [CrossRef] [PubMed]
37. Park, H.J.; Lee, M.K.; Park, Y.B.; Shin, Y.C.; Choi, M.S. Beneficial effects of Undaria pinnatifida ethanol extract
on diet-induced-insulin resistance in C57BL/6J mice. Food Chem. Toxicol. 2011, 49, 727–733. [CrossRef]
[PubMed]
38. Milton-Laskibar, I.; Gómez-Zorita, S.; Aguirre, L.; Fernández-Quintela, A.; González, M.; Portillo, M.P.
Resveratrol-induced effects on body fat differ depending on feeding conditions. Molecules 2017, 22, 2091.
[CrossRef] [PubMed]
39. Shalaby, S.M.; Zakora, M.; Otte, J. Performance of two commonly used angiotensin-converting enzyme
inhibition assays using FA-PGG and HHL as substrates. J. Dairy Res. 2006, 73, 178–186. [CrossRef]
40. Eseberri, I.; Miranda, J.; Lasa, A.; Churruca, I.; Portillo, M.P. Doses of quercetin in the range of serum
concentrations exert delipidating effects in 3T3-L1 preadipocytes by acting on different stages of adipogenesis,
but not in mature adipocytes. Oxid. Med. Cell Longev. 2015, 2015, 480943. [CrossRef]
41. González-Montoya, M.; Hernández-Ledesma, B.; Silván, J.M.; Mora-Escobedo, R.; Martínez-Villaluenga, C.
Peptides derived from in vitro gastrointestinal digestion of germinated soybean proteins inhibit human
colon cancer cells proliferation and inflammation. Food Chem. 2018, 242, 75–82. [CrossRef] [PubMed]
42. Livak, K.J.; Schmittgen, T.D. Analysis of relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) Method. Methods 2001, 25, 402–408. [CrossRef] [PubMed]
43. Li, H.; Yoon, J.H.; Won, H.J.; Ji, H.S.; Yuk, H.J.; Park, K.H.; Park, H.Y.; Jeong, T.S. Isotrifoliol inhibits
pro-inflammatory mediators by suppression of TLR/NF-κB and TLR/MAPK signaling in LPS-induced
RAW264.7 cells. Int. Immunopharmacol. 2017, 45, 110–119. [CrossRef]
44. Ariemma, F.; D’Esposito, V.; Liguoro, D.; Oriente, F.; Cabaro, S.; Liotti, A.; Cimmino, I.; Longo, M.;
Beguinot, F.; Formisano, P.; et al. Low-dose bisphenol—A impairs adipogenesis and generates dysfunctional
3T3-L1 Adipocytes. PLoS ONE 2016, 11, e0150762. [CrossRef] [PubMed]
45. Zhong, W.; Zhao, Y.; Sun, X.; Song, Z.; McClain, C.J.; Zhou, Z. Dietary zinc deficiency exaggerates
ethanol-induced liver injury in mice: Involvement of intrahepatic and extrahepatic factors. PLoS ONE
2013, 8, e76522. [CrossRef] [PubMed]
Mar. Drugs 2018, 16, 512 18 of 18
46. Martin-Diana, A.B.; Izquierdo, N.; Albertos, I.; Sanchez, M.S.; Herrero, A.; Sanz, M.A.; Rico, D. Valorization
of carob’s germ and seed peel as natural antioxidant ingredients in gluten-free crackers. J. Food Process.
Preserv. 2016, 41, e12770. [CrossRef]
47. Reeves, P.; Nielsen, F.; Fahey, G.J. AIN-93 purified diets for laboratory rodents: Final report of the American
Institute of Nutrition ad hoc writing committee on the reformulation of the AIN-76A rodent diet. J. Nutr.
1993, 123, 1939–1951. [CrossRef] [PubMed]
© 2018 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access
article distributed under the terms and conditions of the Creative Commons Attribution
(CC BY) license (http://creativecommons.org/licenses/by/4.0/).
